CARLSBAD, Calif., March 7, 2017 /PRNewswire/ -- An experienced management team, led by Joseph
Headquartered in Carlsbad, California, Genoptix is a recognized leader in its field, and is one of the largest hematopathology centers in the United States. Since 1999, Genoptix has worked with thousands of oncologists and pathologists across the country, providing a comprehensive suite of testing solutions in hematology and solid tumor molecular profiling. More recently, Genoptix pioneered the development and commercialization of a number of proprietary technologies, such as Next Generation Sequencing (NGS) panels based on clinically validated markers.
Joseph M. Limber, who previously served as CEO of Prometheus Laboratories, will lead the new Genoptix as Chief Executive Officer. He will be joined by Mark Spring as Chief Financial Officer and Juan Estruch as Head of Corporate Development, both of whom served with Limber on the executive team at Prometheus Laboratories.
"We are extremely excited to continue to build on the Genoptix brand and renowned history in the field of oncology molecular diagnostics," said Limber. "Together with the committed employees of Genoptix, we look forward to continuing to innovate and expand our outstanding suite of services and solutions that provide powerful informational tools for clinicians to ultimately improve patient care."
About Ampersand Capital PartnersAmpersand is a private equity firm with a focus on growth equity investments in the healthcare sector. Over the past two decades, Ampersand has managed more than $1 billion in private equity partnerships. Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Additional information about Ampersand is available at www.ampersandcapital.com.
About 1315 Capital1315 Capital provides expansion and growth capital to commercial-stage specialty pharmaceutical, medical technology, and healthcare services companies. 1315 Capital leverages experienced investors and proven operating teams to work alongside portfolio company management to rapidly grow platform companies into high value businesses that positively impact patients, physicians, and the broader healthcare system. For more information, visit http://www.1315capital.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ampersand-capital-partners-and-1315-capital-close-transaction-to-acquire-genoptix-300419063.html
SOURCE 1315 Capital
Subscribe to our Free Newsletters!
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...
Find out about travel shots or vaccination before you travel to your destination country. Travel ...
Hay fever is caused by allergy to pollen and is characterized by runny or blocked nose, sneezing, ...View All